GENE ONLINE|News &
Opinion
Blog

COVID-19 Vaccine
U.S. Government Awards $1.4 Billion to Advance COVID Therapies and Vaccines
2023-08-29
Strategic Collaboration Between SK Bioscience and Novavax: Accelerating Vaccine Research and Global Expansion
2023-08-24
CDC Calls an End to J&J’s COVID-19 Vaccine in the U.S.
2023-05-25
Novavax Begins Phase 2 For COVID-19/Influenza Combination And Stand-Alone Flu Shots
2023-01-03
GeneOnline’s Pick: Top 10 Industry News Stories in 2022
2022-12-26
Sanofi, GSK Secure European COVID-19 Booster Approval, AstraZeneca Withdraws U.S. Application
2022-11-10
Pfizer and BioNTech Kickstart Trial For Combination Vaccine for Influenza and COVID-19
2022-11-04
Pfizer to Raise COVID-19 Vaccine Prices Amidst Rising Flu Cases
2022-10-24
AstraZeneca’s Role in COVID-19 Slows Down as World Looks to mRNA Vaccines
2022-08-31
Pfizer and BioNTech’s New Bivalent Omicron Vaccine Lined Up for Authorization from the FDA
2022-08-22
European Commision Purchases an additional 15 million Moderna Bivalent COVID-19 Vaccines
2022-08-09
Novavax Requires Extra Warnings One Day After Receiving Emergency Use Authorization
2022-07-18
Inhaling Immunity: UNC Research on Inhalable COVID Vaccines
2022-07-15
CureVac Files mRNA Patent Lawsuit Against BioNTech in Germany
2022-07-06
Shenzhen Joincare Plots $300 Million IPO On Swiss Exchange
2022-06-20
1 2 3 4
LATEST
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
Partnership to Manufacture Antibiotic to Combat Antimicrobial Resistance
2023-09-25
Revolutionary Technology Aims to Detect and Prevent Dementia and Mental Illness
2023-09-22
Connecting Global Biotech, Largest Biotech Event of Thailand Takes Center Stage
2023-09-22
BIOHK2023: A Place Where Biotechnology Meets Financial Economics
2023-09-21
Connecting the Dots: TCELS Leads the Way for Thailand’s Life Sciences and Healthcare Innovations
2023-09-20
Deceptive Health Advice on TikTok Raises Concerns About Gynecologic Cancer Misinformation
2023-09-20
EVENT
2023-10-04
BioFuture 2023
New York city,USA
Scroll to Top